NonAlcoholic SteatoHepatitis (NASH), now called Metabolic Dysfunction-Associated SteatoHepatitis (MASH), affects almost 115 million adults globally and is the most
Our scientific and medical team will help you define impactful endpoints, select the most relevant questionnaires, and determine the ideal data collection method tailored to your project’s needs.
Our scientific and medical team is dedicated to providing you with customized eCOA strategy recommendations that will propel your project forward:
NonAlcoholic SteatoHepatitis (NASH), now called Metabolic Dysfunction-Associated SteatoHepatitis (MASH), affects almost 115 million adults globally and is the most
In contrast to paper solutions, electronic Clinical Outcome Assessment (eCOA) demonstrates strengths such as: Accuracy Completeness Timings Attributability User-friendliness
Early phase clinical research (phase 1 and 2a) focuses on characterizing the behavior of the investigational product in humans,
Kayentis Europe
19 bis, chemin du vieux Chêne
38240 Meylan
France
Phone: +33 (0)4 76 00 54 20
Kayentis US
186 South Street
Suite 600
Boston, Massachusetts 02111
USA